Skip to main content

Table 1 Characteristics of all the eligible studies

From: LAPTM4B polymorphism increases susceptibility to multiple cancers in Chinese populations: a meta-analysis

First author

Year

Control source

Cancer types

Genotyping method

Case/control

HWE

Case

Control

       

*1/1

*1/2

*2/2

*1/1

*1/2

*2/2

Sun

2008

PB

Liver cancer

PCR

190/175

0.587

72

110

8

99

67

9

Qi

2010

HB

Liver cancer

PCR

86/78

0.799

27

51

8

36

34

7

Zhai

2012

PB

Hepatocellular carcinoma

PCR

102/135

 

37

52

13

   

Wang

2011

HB

Primary liver cancer

PCR

303/515

0.941

107

156

40

272

205

38

Deng

2005

HB

Lung cancer

PCR

162/134

0.285

54

91

21

67

59

8

Li

2006

PB

Lung cancer

PCR

131/104

0.155

70

56

5

57

36

11

Li

2012

HB

Breast cancer

PCR

208/211

0.185

90

100

18

129

76

6

Fan

2012

HB

Breast cancer

PCR

732/649

0.356

326

342

64

346

262

41

Yang

2012

PB

Gallbladder carcinoma

PCR

91/155

0.851

34

45

12

88

57

10

Wang

2013

HB

Nasopharyngeal carcinoma

PCR

134/327

0.07

74

48

12

163

145

19

Wang

2010

HB

Pancreatic cancer

PCR

58/156

0.977

24

26

8

74

67

15

Xu

2012

HB

Ovarian cancer

PCR

282/365

0.64

122

115

45

231

108

26

Meng

2011

HB

Cervical carcinoma

PCR

317/416

0.835

127

153

37

225

163

28

Meng

2013

HB

Endometrial carcinoma

PCR-RFLP

283/378

0.072

93

135

55

200

140

38

Liu

2007

HB

Gastric cancer

PCR

214/350

0.484

88

107

19

199

133

18

Cheng

2008

HB

Colon/rectal/esophageal cancer

PCR

701/350

0.484

362

293

46

199

133

18

Sun

2007

HB

Lymphoma

PCR

166/350

0.484

72

71

23

199

133

18

  1. HB hospital-based, PB population-based, HWE Hardy-Weinberg Equilibrium, PCR polymerase chain reaction, PCR-RFLP polymerase chain reaction–restriction fragment length polymorphism.